Skip to main content
ORTIN GLOBAL LIMITED logo

ORTIN GLOBAL LIMITED — Investor Relations & Filings

Ticker · ORTINGLOBE ISIN · INE749B01020 BSE.NS Manufacturing
Open in API
Filings indexed 204 across all filing types
Latest filing 2024-05-30 Annual Report
Country IN India
Listing BSE.NS ORTINGLOBE

About ORTIN GLOBAL LIMITED

https://www.ortinlabsindia.com/

Ortin Global Limited is a pharmaceutical enterprise engaged in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs), intermediates, and finished dosage formulations. The company maintains a diverse product portfolio covering various therapeutic segments, such as anti-diabetics, anti-hypertensives, anti-retrovirals, analgesics, and anti-pyretics. Its operations include the synthesis of complex chemical molecules and the production of oral solids and liquids, including tablets, capsules, and syrups. With a focus on integrated manufacturing processes, the company serves both domestic and international healthcare markets. Ortin Global Limited prioritizes research and development to expand its product offerings and optimize production techniques, ensuring compliance with established quality standards across its manufacturing facilities.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Annual Report Classification · 95% confidence The document is a detailed communication from Ortin Laboratories Limited dated 30.05.2024, addressed to stock exchanges, reporting the outcome of a Board Meeting where the audited financial results for the quarter and year ended 31.03.2024 were considered and approved. It includes the audited financial results, auditors' report with unmodified opinion, and changes in registered office address. The document contains substantive financial data such as income, expenses, profit/loss, tax expenses, earnings per share, and notes on accounting standards and audit committee approval. The presence of full financial statements and audit report indicates this is a comprehensive financial report for the fiscal year. It is not merely an announcement or a certification but contains the actual audited financial results and related disclosures. Therefore, this document fits the definition of an Annual Report (10-K equivalent) or a full-year audited financial report. Given the Indian context and the detailed financial data for the full fiscal year, the best fitting category is Annual Report (10-K).
2024-05-30 English
Board Meeting — ORTIN LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 30-May-2024 to inter-alia consider and approve the Audited Financial results of the Company for…
Regulatory Filings
2024-05-22 English
Board Meeting — Financial Results
Regulatory Filings Classification · 100% confidence The document text is extremely short (112 characters) and contains only a digital signature with no substantive content or financial data. There is no indication of any report, announcement, or detailed information. Given the lack of content, this is best classified as a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous filings that do not fit other specific categories.
2024-05-22 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 100% confidence The document is a disclosure under Regulation 31(4) & (5) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. It declares the promoters' shareholding and confirms no encumbrance of shares during the financial year ended March 31, 2024. This is a notification about share ownership levels by promoters, which fits the definition of a Major Shareholding Notification (MRQ). The document is short and focused on shareholding disclosure, not a full report or announcement of voting results or other categories.
2024-05-10 English
Reply to Clarification Sought
Board/Management Information Classification · 100% confidence The document is a formal disclosure addressed to stock exchanges (BSE and NSE) regarding the appointment of two additional directors to the company's board. It references Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to disclosure of material events including changes in board composition. The content includes details about the appointees, their profiles, and compliance statements. There are no financial statements, earnings data, or report attachments. The document is clearly an announcement of changes in the company's board of directors, fitting the category of Board/Management Information (MANG). The document length is 3579 characters, which is short and focused solely on management changes, not a full report or announcement of a report publication.
2024-05-07 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a Compliance Certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018, for the quarter and year ended 31.03.2024. It is addressed to stock exchanges and certifies that details of securities dematerialized/rematerialized have been furnished as required. The document is a certificate of compliance rather than a financial report or announcement of financial results. It is also relatively short (3010 characters) and primarily serves as a regulatory attestation. According to the rules, such officer certifications or compliance certificates should be classified as Regulatory Filings (RNS).
2024-04-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.